



Control Fee Medicinal Products – Guidelines

Contents:

- [The regulation](#)
- [Why pay the fee?](#)
- [Who shall pay the fee?](#)
- [When to report liable turnover?](#)
- [How is the fee calculated?](#)
- [How to pay the fee?](#)
- [The Fee Form](#)
- [Yearly report and auditor's confirmation](#)
- [No report – insufficient information](#)

The regulation

In accordance with The Regulation Relating to Medicinal Products of December 18th 2009, the Norwegian Medicines Agency collects a control fee from holders of marketing authorizations (MA).

Why pay the fee?

The fee covers expenses for quality control, supervision of adverse events and information activities by the authorities.

Who shall pay the fee?

MA-holders of medicinal products are responsible for reporting liable turnover and paying the fee.

When to report liable turnover?

Report quarterly and no later than thirty days after the quarter has ended, cf. form for reporting. Send the report by e-mail to: kontrollavgift@noma.no

How is the fee calculated?

The fee is based on medicinal products' turnover from each company to the wholesaler (wholesalers net purchasing price). The fee for 2011 is 0,60 % of the turnover.

How to pay the fee?

The Norwegian Medicines Agency sends an invoice to the MA-holder or his representative according to the information received in the fee-form. The payment is due 30 days after the invoice date. In the case of late reporting, payment is due 15 days after the invoice date.

Swiftaddress:
DNBANOKK

Bank account info:

No. 7694.05.00903
Den norske Bank
P.O. Box 1171 Sentrum
0107 Oslo
Norway

Account No. IBAN:
NO71 7694.05.00903

The Fee Form

The form (excel) is available at: www.noma.no

Please fill in the space marked in yellow. The fee will be calculated automatically on the basis of the turnover.

Yearly report and auditor's confirmation

Each year, the MA-holder's auditor confirms the turnover of medicinal products. The auditor should also confirm whether the company has a system for continuous registration of liable turnover and calculation of control fee (cf. reporting form).

The yearly report with the auditor's confirmed signature must be received by The Norwegian Medicines Agency within March 1th 2012.

No report – insufficient information

MA-holders who do not report will receive an invoice with The Norwegian Medicines Agency's estimation of liable turnover.

For further information:

Helga Festøy telephone: 00 47 22 16 84 24

Terje Gregersen telephone: 00 47 22 16 84 04